CATALYST FOR CHANGE
CAR-T CELL THERAPY
01.
ACCELERATING ADOPTION THROUGH COLLABORATION
car-t cell therapy has entered clinical practice, especially for the treatment of b‐cell malignancies, in the us market in 2017 after being granted priority review and breakthrough therapy designations by the fda. in 2018, the most commonly investigated, cd-19 targeted car-t cell therapy was considered by health canada and cadth (pcodr) and inesss.  both cadth and inesss published their recommendations on january 15 2019.

with the almost infinite options in car specificity and design as well as in delivering, regulating, and genome editing to insert the car gene, it is easily conceivable that many more car-t cell‐based products will enter into clinical research in future. this may result in better options for treating solid tumours and for simplifying the car -t cell production process. such a paradigm-shifting and novel cancer therapy that relies on viral production, genetic- modification, cell expansion, quality control/quality analysis, as well as clinical application and toxicity management poses significant challenges to regulatory and reimbursement approval in canada.

colab.paper. car t-cell therapy. accelerating adoption through collaboration
tisagenlecleucel (brand name kymriah) recommendations
CADTH
15 January.2019
recommendation : tisagenlecleucel (kymriah) for pediatric acute lymphoblastic leukemia and diffuse large b-cell lymphoma

INESSS
15 janvier.2019
publication : avis sur le tisagenlecleucel pour le traitement de la leucémie lymphoblastique aiguë récidivante ou réfractaire | avis sur le tisagenlecleucel pour le traitement du lymphome diffus à grandes cellules b récidivant ou réfractaire

Health Canada
5 sepetmber.2018
regulatory decision summary : kymriah

axicabtagene ciloleucel (brand name yescarta) recommendations
CADTH
august 15.2019
recommendation : axicabtagene ciloleucel for large b-cell lymphoma

INESSS
le 21 août.2019
publication : avis portant sur la thérapie cellulaire Yescarta

Heath Canada
february 13.2019
regulatory decision summary : Yescarta

CAR T cell immunotherapy for blood cancers in québec
CAR T cell immunotherapy for blood cancers in québec.
eligibility and procedure 

thérapie immunocellulaires CAR T cell contre les cancers hématologiques au québec.
admissibilité et démarche

cancer care ontario CAR T cell information
getting CAR T cell therapy in canada
eligibility and procedure 
CAR T available at hôpital maisonneuve rosemont | nouveau traitement CAR T maintenant offert à l'hôpital maisonneuve rosemont
INFOGRAPHIC #cartincanada
colab.brief. car t-cell therapy. accelerating adoption through collaboration
november 26.2018
car t-cell therapy. accelerating adoption through collaboration.
download colab.brief pdf
NHS preparing to offer ‘game-changing’ cancer treatment
The Guardian, 26 April 2018
NHS preparing to offer ‘game-changing’ cancer treatment
Health service chief calls for affordable access to CAR-T, which modifies immune system to destroy cancer cells
the cancer collaborative car-t cell therapy initiative is supported with funding by the following organizations